Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

NIH Lab Closed After FDA Finds Fungi in Drugs

By Drug Discovery Trends Editor | June 5, 2015

NIH Clinical Center. (Credit: NIH)A pharmacy at the National Institutes of Health, a key component in ongoing scientific studies, was closed after fungi was found in drugs manufactured there, according to federal authorities.

The Pharmaceutical Development Section suspended work, it was announced by the NIH on Thursday, after two inspections in May of the facility in Bethesda, Md., found violations, according to an announcement.

The fungal contamination was found in two vials of albumin, used in administration of cancer drug interleukin, in April.  Vials from the same batch were used to treat six patients – all of whom are being monitored, but none of whom have been sickened, according to the NIH.

“This is a distressing and unacceptable situation,” said Francis Collins, the director of the NIH, in a statement. “The fact that patients may have been put in harm’s way because of a failure to follow standard operating procedures in the NIH Clinical Center’s Pharmaceutical Development Section is deeply troubling.”

Collins will “personally oversee” the fixes, he added.

READ MORE: Next Generation Phenotypic Screening: Part of a balanced strategy for accelerating drug discovery

Violations found by the FDA at inspections on May 19 and May 29 included flaws in the air-handling system, inadequate quality control, lack of training and non-compliance with standard operating procedures, according to the inspection report.

“Our first responsibility is the safety and care of our patients,” said Collins.

Forty-six studies are going to be affected by the closure of the pharmacy, the NIH said. About 250 patients who are undergoing trials are going to be switched to drugs from other facilities, they added.


Filed Under: Drug Discovery

 

Related Articles Read More >

Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50